Our Pricing

Wegovy Click Dosage Chart vs Mounjaro: Complete Guide

Published on: June 03, 2026

Understanding the wegovy click dosage chart mounjaro comparison UK is essential before starting your weight loss journey. At Cured Pharmacy, our UK-registered clinical team helps patients navigate the distinct dosing protocols of these two MHRA-licensed treatments, ensuring safe escalation and optimal outcomes. Both medications require gradual dose increases to minimise side effects, but their schedules and delivery mechanisms differ significantly.

Wegovy Click Dosage Chart: Understanding the FlexTouch Pen

Wegovy uses the FlexTouch pre-filled pen system, which delivers semaglutide in precisely measured doses without requiring manual dose selection. Each pen contains a fixed dose, eliminating the risk of incorrect dosing. The standard Wegovy escalation schedule begins at 0.25mg weekly for four weeks, progressing through 0.5mg, 1mg, and 1.7mg stages before reaching the maintenance dose of 2.4mg weekly [1].

The 'click' mechanism in Wegovy pens provides audible and tactile feedback during injection, confirming proper dose delivery. Unlike adjustable pens, each Wegovy pen is colour-coded to its specific dose strength, making identification straightforward. Clinical data from the STEP trials showed that gradual dose escalation over 16-20 weeks significantly reduced gastrointestinal side effects compared to faster titration protocols [1][2].

Patients typically spend four weeks at each dose level, allowing the body to adapt to increasing semaglutide concentrations. This methodical approach, whilst requiring patience, correlates with better treatment adherence and fewer discontinuations due to nausea or vomiting. Your UK prescriber may adjust this timeline based on individual tolerance and response.

Wegovy Dose Escalation Timeline

The complete Wegovy titration schedule spans approximately 16-20 weeks: Weeks 1-4 at 0.25mg, Weeks 5-8 at 0.5mg, Weeks 9-12 at 1mg, Weeks 13-16 at 1.7mg, and Week 17 onwards at the maintenance dose of 2.4mg. Missing more than two consecutive doses may require restarting at a lower dose to avoid increased side effects, as outlined in the UK Summary of Product Characteristics [2].

Mounjaro KwikPen Dosage Chart: Dual-Action Titration Protocol

Mounjaro employs the KwikPen delivery system, which also provides pre-filled, single-dose injections of tirzepatide. The standard UK-licensed escalation begins at 2.5mg weekly for four weeks, then increases to 5mg for another four weeks. Depending on clinical response and tolerability, prescribers may further escalate to 7.5mg, 10mg, 12.5mg, or the maximum licensed dose of 15mg weekly [3].

Each Mounjaro KwikPen is clearly labelled with its dose strength and features an intuitive push-button mechanism. The pen's design includes a dose window that confirms successful injection and a hidden needle that retracts automatically after use. In the SURMOUNT-1 trial, patients on the 15mg maintenance dose achieved an average 22.5% body weight reduction over 72 weeks, significantly exceeding results seen with semaglutide-based treatments [3][4].

The Mounjaro escalation schedule is more flexible than Wegovy's, allowing prescribers to pause at intermediate doses (7.5mg or 10mg) if patients achieve satisfactory weight loss without requiring maximum dosing. This individualised approach, supported by MHRA guidance, balances efficacy with tolerability and cost considerations.

Mounjaro Dose Progression Options

Typical Mounjaro titration follows this pattern: Weeks 1-4 at 2.5mg, Weeks 5-8 at 5mg, with optional escalation every four weeks thereafter to 7.5mg, 10mg, 12.5mg, or 15mg based on individual response. Unlike Wegovy's fixed progression to 2.4mg, Mounjaro allows maintenance at any tolerated dose that achieves clinical goals, as demonstrated in the SURPASS trials [3][4].

Wegovy vs Mounjaro Dosing: Key Differences for UK Patients

The fundamental difference lies in their pharmacological mechanisms: semaglutide (Wegovy) is a selective GLP-1 receptor agonist, whilst tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors. This dual-action approach in Mounjaro produces more pronounced effects on insulin secretion, glucagon suppression, and appetite regulation, which explains the higher average weight loss observed in head-to-head comparisons [4][5].

Dosing frequency is identical—both require once-weekly subcutaneous injection—but their escalation timelines differ. Wegovy follows a rigid five-stage protocol ending at 2.4mg, whilst Mounjaro offers six potential maintenance doses ranging from 5mg to 15mg. This flexibility in Mounjaro dosing allows UK prescribers to tailor treatment more precisely to individual patient needs and tolerance thresholds.

From a practical standpoint, both pen systems are designed for ease of use, with pre-filled doses eliminating the need for manual measurement. However, Mounjaro's higher starting dose (2.5mg versus Wegovy's 0.25mg) reflects tirzepatide's different pharmacokinetic profile and generally favourable tolerability, as evidenced by comparable discontinuation rates despite the tenfold dose difference at initiation [3][5].

Clinical Outcomes: Comparative Efficacy Data

In the SURMOUNT-1 trial, tirzepatide 15mg produced an average 22.5% total body weight reduction, compared to approximately 14.9% with semaglutide 2.4mg in the STEP-1 trial [1][3]. Whilst cross-trial comparisons have limitations, these findings suggest Mounjaro may offer superior weight loss for patients who tolerate higher doses, though both medications significantly outperform placebo and lifestyle interventions alone.

How to Use Wegovy and Mounjaro Pens Correctly

Both injection systems are designed for subcutaneous administration into the abdomen, thigh, or upper arm. Before each injection, inspect the pen for particulates or discolouration, and ensure the medication has reached room temperature (remove from the refrigerator 30 minutes prior). Rotate injection sites weekly to prevent lipohypertrophy, a localised tissue change that can affect medication absorption [6].

For Wegovy FlexTouch pens: Remove the outer cap, attach a new needle, perform the safety test by dialling to the flow check symbol, select your prescribed dose, insert the needle at 90 degrees, press and hold the dose button until the counter returns to zero, then count to six before withdrawing. The pen will click during injection, confirming dose delivery [2].

For Mounjaro KwikPens: Remove the base cap, place the pen against your injection site, press and hold the purple injection button until you hear a second click (approximately 5-10 seconds), then withdraw the needle. The dose window will show a grey plunger, confirming complete delivery. Never reuse needles, and dispose of used pens in a sharps container as per UK regulations [3].

Common injection errors include injecting too quickly, failing to complete the full injection time, or reusing needles. If you miss a dose, administer it within five days of the scheduled time; if more than five days have passed, skip that dose and resume your regular schedule. Never double-dose to compensate for missed injections, as this increases the risk of severe nausea and vomiting [2][6].

Managing Side Effects During Dose Escalation

Gastrointestinal side effects—particularly nausea, vomiting, diarrhoea, and constipation—are the most commonly reported adverse events with both medications, typically peaking during dose escalation phases. In clinical trials, approximately 44% of Wegovy patients and 34% of Mounjaro patients experienced nausea, though most cases were mild to moderate and resolved within 4-8 weeks [1][3].

To minimise GI symptoms, eat smaller, more frequent meals, avoid high-fat foods immediately after injection, and stay well-hydrated. Ginger tea, peppermint, and over-the-counter antiemetics like domperidone (subject to prescriber approval) may provide relief. If symptoms become severe or persistent, contact your prescriber—they may recommend pausing escalation or temporarily reducing your dose [6].

Rare but serious side effects include pancreatitis (characterised by severe abdominal pain radiating to the back), gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications. Mounjaro and Wegovy both carry warnings about thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans. Both medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2][3][5].

Accessing Wegovy and Mounjaro Through Cured Pharmacy

At Cured Pharmacy, we provide transparent upfront pricing for both treatments, with Mounjaro available from £124.99 and Wegovy from £135.00, subject to clinical assessment by our UK-registered prescribers. Our online consultation takes under three minutes and evaluates your medical history, current medications, weight loss goals, and any contraindications to ensure safe prescribing in line with MHRA and NICE guidelines.

All medications dispensed by Cured Pharmacy are sourced from UK-licensed wholesalers and manufactured to GPhC standards. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees every prescription to ensure accuracy and appropriateness. We offer discreet packaging and reliable delivery across the UK, with full patient support throughout your treatment journey.

Choosing between Wegovy and Mounjaro depends on multiple factors: your weight loss targets, tolerance to GI side effects, previous treatment responses, and budget considerations. Our clinical team will discuss these variables during your consultation and recommend the most suitable option. Both medications require ongoing commitment to dietary modifications and increased physical activity for optimal results, as demonstrated across all major clinical trials [1][3][4].

Starting Your Weight Loss Journey

To begin treatment, complete our free online consultation at Cured Pharmacy. If approved, your prescription will be dispensed by our UK-registered pharmacy team and dispatched in discreet packaging. You'll receive full injection instructions, dose escalation guidance, and access to our patient support line for any questions during treatment. Regular follow-ups with your prescriber ensure safe progression through dose escalation and monitoring for adverse effects.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro (tirzepatide): UK Summary of Product Characteristics. GOV.UK. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. NICE Technology Appraisal Guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and lifestyle changes.